Trial Profile
Phase Ib multiple ascending dose trial of DB 959 in volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2012
Price :
$35
*
At a glance
- Drugs T3D 959 (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 08 Nov 2011 Status changed from recruiting to completed.
- 01 Nov 2011 Positive results from this trial presented in a DARA Biosciences media release.